Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

PURPOSE: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). PATIENTS AND METHODS: Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared patients treated with venetoclax +...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollyea, Daniel A., DiNardo, Courtney D., Arellano, Martha L., Pigneux, Arnaud, Fiedler, Walter, Konopleva, Marina, Rizzieri, David A., Smith, B. Douglas, Shinagawa, Atsushi, Lemoli, Roberto M., Dail, Monique, Duan, Yinghui, Chyla, Brenda, Potluri, Jalaja, Miller, Catherine L., Kantarjian, Hagop M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365354/
https://www.ncbi.nlm.nih.gov/pubmed/35046058
http://dx.doi.org/10.1158/1078-0432.CCR-21-3467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365354/
https://www.ncbi.nlm.nih.gov/pubmed/35046058
http://dx.doi.org/10.1158/1078-0432.CCR-21-3467

Ejemplares similares